Niagen Bioscience Q2 Sales Miss, Net Income Plunges 73%
NAGE is trading near its 52-week low of $3.115 (2.7% above the low).
Summary
Niagen Bioscience reported Q2 net sales of $29.79M, missing the $30.69M consensus, while net income collapsed to $963K from $3.6M a year ago. The miss comes as the stock trades near its 52-week low of $3.12, down from $11.29. Management launched a telehealth platform and a rare-disease pharma program, but also guided for higher 2026 operating expenses and a weaker ingredient business. This follows a Q1 where operating income dropped 67% and the company activated a $50M ATM offering. The direct-to-consumer segment grew 23%, but that wasn't enough to offset broader headwinds. With six analysts still at 'strong buy' and a median target of $11, the gap between expectations and reality is widening.
At the time of this announcement, NAGE was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.4M. The 52-week trading range was $3.12 to $11.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.